Generic Imatinib Approved in the US for CML: What does it mean for GIST patients? - The Life Raft Group

Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members, BMC Gastroenterology

PDF) Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet

Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing

The State of GIST Treatments - The Life Raft Group

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (

Novartis Archives - The Life Raft Group

generic imatinib Archives - The Life Raft Group

Introduction: Biomedical Innovation and Policy in the Twenty-First Century

Imatinib Mesylate — A New Oral Targeted Therapy

Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib

Generic Imatinib Leaflet

The State of GIST Treatments - The Life Raft Group

Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry, Clinical Sarcoma Research